KR20230016636A - 알츠하이머병과 관련된 불안을 치료하는 방법 - Google Patents

알츠하이머병과 관련된 불안을 치료하는 방법 Download PDF

Info

Publication number
KR20230016636A
KR20230016636A KR1020227041229A KR20227041229A KR20230016636A KR 20230016636 A KR20230016636 A KR 20230016636A KR 1020227041229 A KR1020227041229 A KR 1020227041229A KR 20227041229 A KR20227041229 A KR 20227041229A KR 20230016636 A KR20230016636 A KR 20230016636A
Authority
KR
South Korea
Prior art keywords
patient
cmai
score
administering step
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227041229A
Other languages
English (en)
Korean (ko)
Inventor
산제이 두베
Original Assignee
아바니르 파마슈티컬스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아바니르 파마슈티컬스, 인코포레이티드 filed Critical 아바니르 파마슈티컬스, 인코포레이티드
Publication of KR20230016636A publication Critical patent/KR20230016636A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227041229A 2020-04-27 2021-04-26 알츠하이머병과 관련된 불안을 치료하는 방법 Pending KR20230016636A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016270P 2020-04-27 2020-04-27
US63/016,270 2020-04-27
PCT/US2021/029246 WO2021222145A1 (en) 2020-04-27 2021-04-26 Methomethods of treating agitation associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20230016636A true KR20230016636A (ko) 2023-02-02

Family

ID=75914613

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227041229A Pending KR20230016636A (ko) 2020-04-27 2021-04-26 알츠하이머병과 관련된 불안을 치료하는 방법

Country Status (13)

Country Link
US (1) US20230270738A1 (enExample)
EP (1) EP4142729A1 (enExample)
JP (1) JP2023523373A (enExample)
KR (1) KR20230016636A (enExample)
CN (1) CN115734787A (enExample)
AU (1) AU2021263354A1 (enExample)
BR (1) BR112022021535A2 (enExample)
CA (1) CA3176234A1 (enExample)
IL (1) IL296977A (enExample)
MX (1) MX2022013427A (enExample)
PH (1) PH12022552764A1 (enExample)
TW (1) TW202203922A (enExample)
WO (1) WO2021222145A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2792662T3 (da) 2007-05-01 2016-07-25 Concert Pharmaceuticals Inc Morphinanforbindelser
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
KR20240110812A (ko) * 2021-10-27 2024-07-16 아바니르 파마슈티컬스, 인코포레이티드 알츠하이머병과 관련된 불안을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US20160143901A1 (en) * 2006-02-03 2016-05-26 Avanir Pharmaceuticals, Inc. Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of agitation in dementia
MX370608B (es) 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
TWI869633B (zh) * 2014-09-14 2025-01-11 美商阿瓦尼爾製藥股份有限公司 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物

Also Published As

Publication number Publication date
EP4142729A1 (en) 2023-03-08
IL296977A (en) 2022-12-01
WO2021222145A1 (en) 2021-11-04
BR112022021535A2 (pt) 2023-01-24
US20230270738A1 (en) 2023-08-31
TW202203922A (zh) 2022-02-01
WO2021222145A8 (en) 2021-12-30
PH12022552764A1 (en) 2024-03-25
MX2022013427A (es) 2023-01-19
AU2021263354A1 (en) 2022-10-27
JP2023523373A (ja) 2023-06-02
CN115734787A (zh) 2023-03-03
CA3176234A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
KR102316933B1 (ko) 헌팅턴병 치료를 위한 프리도피딘의 용도
US11090297B2 (en) Pridopidine for treating huntington's disease
EP3311373B1 (en) Devices and methods for drug administration and mixing, and training of proper techniques therefor
CN110891558A (zh) 使用芬氟拉明治疗多泽综合征的方法
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
US20230270738A1 (en) Methods of treating agitation associated with alzheimer's disease
JP2020530032A (ja) ３−メチルメトカチノンの使用
Oslin et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
US20230131493A1 (en) Methods of treating agitation associated with alzheimer's disease
Haghparast et al. Sedatives and hypnotics
US20240408086A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
Alfonso Understanding the psychodynamics of nonadherence
HK40089955A (en) Methods of treating agitation associated with alzheimer's disease
CN118510513A (zh) 治疗与阿尔茨海默氏病相关的激越的方法
US20250295648A1 (en) Method for treating l-dopa-induced dyskinesia, parkinson's disease, or parkinson's disease motor disability using befiradol
Haq et al. Bipolar disorder and tuberous sclerosis complex: is it a mere coincidence?
Ayvaci et al. Pharmacotherapy for depression.
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
Narang et al. Pharmacotherapy for Insomnia
Diaz-Marsa et al. THE INTERNATIONAL JOURNAL OF NEUROPS YC HI ATR IC MEDICINE
Mancano New drugs of 2012, part I
EFFEXOR HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use EFFEXOR XR safely and effectively. See full prescribing information for

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902